Effect of Moxifloxacin plus Pretomanid against Mycobacterium tuberculosis in Log Phase, Acid Phase, and Nonreplicating-Persister Phase in an In Vitro Assay-Reference-Cited by-同舟云学术

Effect of Moxifloxacin plus Pretomanid against Mycobacterium tuberculosis in Log Phase, Acid Phase, and Nonreplicating-Persister Phase in an In Vitro Assay

Published:2019-01 Issue:1 Volume:63 Page:
ISSN:0066-4804
Container-title:Antimicrobial Agents and Chemotherapy
language:en
Short-container-title:Antimicrob Agents Chemother

Author:

de Miranda Silva Carolina¹,Hajihosseini Amirhossein¹,Myrick Jenny²,Nole Jocelyn²,Louie Arnold²,Schmidt Stephan¹,Drusano George L.²

Affiliation:

1. Center for Pharmacometrics & Systems Pharmacology, Department of Pharmaceutics, College of Pharmacy, University of Florida, Orlando, Florida, USA

2. Institute for Therapeutic Innovation, College of Medicine, University of Florida, Orlando, Florida, USA

Abstract

Combination therapy is a successful approach to treat tuberculosis in patients with susceptible strains of Mycobacterium tuberculosis . However, the emergence of resistant strains requires identification of new, effective therapies.

Funder

HHS | NIH | National Institute of Allergy and Infectious Diseases

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology

Link

https://journals.asm.org/doi/pdf/10.1128/AAC.01695-18

Reference27 articles.

1. World Health Organization. 2017. Diagnosis and treatment: TB, HIV-associated TB and drug-resistant TB, p 63–96. In Global tuberculosis report 2017. World Health Organization, Geneva, Switzerland. http://www.who.int/tb/publications/global_report/en/. Accessed 23 March 2018.

2. Analysis of Combination Drug Therapy to Develop Regimens with Shortened Duration of Treatment for Tuberculosis

3. Four-Month Moxifloxacin-Based Regimens for Drug-Sensitive Tuberculosis

4. The Combination of Rifampin plus Moxifloxacin Is Synergistic for Suppression of Resistance but Antagonistic for Cell Kill of Mycobacterium tuberculosis as Determined in a Hollow-Fiber Infection Model

5. A small-molecule nitroimidazopyran drug candidate for the treatment of tuberculosis

Cited by 24 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Pharmacokinetics–Pharmacodynamics Modeling for Evaluating Drug–Drug Interactions in Polypharmacy: Development and Challenges;Clinical Pharmacokinetics;2024-06-18

2. QT-Interval Prolongation in the Treatment of Drug-Resistant Tuberculosis;Antibiot Khimioter = Antibiotics and Chemotherapy;2024-03-27

3. A quality-by-design strategic approach for the development of bedaquiline-pretomanid nanoparticles as inhalable dry powders for TB treatment;International Journal of Pharmaceutics;2024-03

4. Tools to develop antibiotic combinations that target drug tolerance in Mycobacterium tuberculosis;Frontiers in Cellular and Infection Microbiology;2023-01-06

5. Cholesterol-dependent activity of dapsone against non-replicating persistent mycobacteria;Microbiology;2022-12-13